FDA Grants IND Clearance for ALLO-501, an Allogeneic CAR-T Candidate

Initiation of a phase 1 clinical trial of ALLO-501, an allogeneic CAR-T candidate, in patients with NHL is planned for early 2019.

from Latest articles from Cancer Therapy Advisor Hematologic Cancers http://bit.ly/2TmGIoV